Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V181 (Dengue Vaccine) Potency Study in Healthy Adults
NCT05507450Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2022
- Primary completion
- Jun 2023
- Modality
- Live Attenuated Vaccines
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of TetraVax-DV in dengue fever (4 arms), sponsored by Merck & Co. Primary endpoints: Dengue Virus-Neutralizing Antibody Titers (GMTs) at Day 28 and Percentage of Participants With Vaccine-Related Serious Adverse Events (SAEs) at 28 days. Started Sep 2022; status: completed.
02
Drugs
TetraVax-DV
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT05507450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05507450.